HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 13 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Sinopharm Group (1099.HK) - Industry Trends Hardly Support High Valuation Expectations

China Resources Pharmaceutical (3320.HK) - Here Are the Concerns

Zhangzhou Pientzehuang Pharmaceutical (600436.CH) - Disappointing Performance Is Just the Beginning

Taiwan Strait Dispute and China-US Tension: The Impact on China Healthcare

Huadong Medicine Co Ltd (000963.CH) - The Medical Cosmetology Business Is the Key Breakthrough Point

Huadong Medicine Co Ltd (000963.CH) - A “Dark Horse” to Reverse Performance Dilemma

Gravity Works As WeWork Doesn't; Now Plan B

Equity Bottom-Up

Huadong Medicine Co Ltd A / Equity Bottom-Up

<ul>
<li>Huadong released encouraging 2022H1 results. After a significant decline due to the loss of VBP bid for core varieties, Huadong is out of trouble and back on track now.</li>
<li>The future profit contribution would be on medical cosmetology and industrial microorganisms businesses. For 2022 forecast, revenue YoY growth is below 10%, and net profit YoY growth is above 15%.</li>
<li>Due to unfriendly macro environment, Huadong's share price could face a correction. But based on its promising outlook, we recommend that investors could take advantage of the pullback to long.</li>
</ul>


Huadong released encouraging 2022H1 results. After a significant decline due to the loss of VBP bid for core varieties, Huadong is out of trouble and back on track now.
The future profit contribution would be on medical cosmetology and industrial microorganisms businesses. For 2022 forecast, revenue YoY growth is below 10%, and net profit YoY growth is above 15%.
Due to unfriendly macro environment, Huadong's share price could face a correction. But based on its promising outlook, we recommend that investors could take advantage of the pullback to long.


Huadong Medicine (000963.CH) 2022H1 - Huadong Is Back on Track. If Shares Pullback, Then Be Long